It included patients with completely resected NSCLC and found that patients with ERCC1-negative tumors benefited from adjuvant cisplatin-based chemotherapy but patients with ERCC1-positive tumors did not [24]. Here, ERCC1 is linked to non-small cell lung carcinoma.